NON APPLICABILITY CERTIFICATE UNDER REGULATION 57(5) FOR THE QUARTER ENDED 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs Ltd has submitted a non-applicability certificate to BSE under SEBI Regulation 57(5) for the quarter ended 31 December 2025. The company has confirmed that the regulation does not apply to it because it does not have any non-convertible securities (such as NCDs or preference shares) outstanding for which interest, dividend, or principal repayment was due during the quarter. This is a routine compliance filing with no outstanding debt obligations of this nature on its books. The certificate was signed and dated 6 January 2026 and submitted under BSE scrip code 524606.
No financial impact on shareholders — this is purely a regulatory disclosure confirming that Beryl Drugs has no non-convertible debt or preference share obligations to report. Investors should note that the company is not raising funds through such instruments, and there is no effect on stock price from this filing.